AU2020229316A1 - Compositions including cinnamic acid and methods of use thereof - Google Patents

Compositions including cinnamic acid and methods of use thereof Download PDF

Info

Publication number
AU2020229316A1
AU2020229316A1 AU2020229316A AU2020229316A AU2020229316A1 AU 2020229316 A1 AU2020229316 A1 AU 2020229316A1 AU 2020229316 A AU2020229316 A AU 2020229316A AU 2020229316 A AU2020229316 A AU 2020229316A AU 2020229316 A1 AU2020229316 A1 AU 2020229316A1
Authority
AU
Australia
Prior art keywords
patient
cinnamic acid
composition
pharmaceutical composition
glyceryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020229316A
Other languages
English (en)
Inventor
Kalipada PAHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush University Medical Center
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of AU2020229316A1 publication Critical patent/AU2020229316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020229316A 2019-02-25 2020-02-25 Compositions including cinnamic acid and methods of use thereof Abandoned AU2020229316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810055P 2019-02-25 2019-02-25
US62/810,055 2019-02-25
PCT/US2020/019568 WO2020176432A1 (en) 2019-02-25 2020-02-25 Compositions including cinnamic acid and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2020229316A1 true AU2020229316A1 (en) 2021-09-16

Family

ID=72238701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020229316A Abandoned AU2020229316A1 (en) 2019-02-25 2020-02-25 Compositions including cinnamic acid and methods of use thereof

Country Status (9)

Country Link
US (1) US12478598B2 (enExample)
EP (1) EP3930704A4 (enExample)
JP (1) JP2022521233A (enExample)
KR (1) KR20210130772A (enExample)
CN (1) CN113473981A (enExample)
AU (1) AU2020229316A1 (enExample)
CA (1) CA3130761A1 (enExample)
EA (1) EA202192199A1 (enExample)
WO (1) WO2020176432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202002639D0 (en) * 2020-02-25 2020-04-08 Ucl Business Ltd Therapy
WO2022093922A1 (en) * 2020-10-28 2022-05-05 Rush University Medical Center Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
US20240350441A1 (en) * 2021-12-01 2024-10-24 Sava Healthcare Ltd Pharmaceutical formulation and a process for its preparation
US20250057793A1 (en) * 2021-12-16 2025-02-20 The United States Government As Represented By The Department Of Veterans Affairs Benzoic acid salts for treatment of nervous system injuries and disorders
WO2024201533A1 (en) * 2023-03-31 2024-10-03 Sava Healthcare Limited A parenteral composition of cinnamic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100479405B1 (ko) * 2002-05-24 2005-03-30 주식회사 싸이제닉 신남산 이합체, 그 제조방법 및 퇴행성 뇌질환 치료를위한 그의 용도
HUE053671T2 (hu) * 2014-01-17 2021-07-28 Univ Rush Medical Center Gliceril-tribenzoátot tartalmazó készítmény neurodegeneratív rendellenességben történõ alkalmazása
ES2799309T3 (es) * 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
EP4026545A1 (en) * 2014-11-19 2022-07-13 Rush University Medical Center Compositions and methods for treating lysosomal disorders
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
EP3691630A4 (en) * 2017-10-06 2021-10-27 Rush University Medical Center USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY
GB202002639D0 (en) 2020-02-25 2020-04-08 Ucl Business Ltd Therapy
WO2022093922A1 (en) * 2020-10-28 2022-05-05 Rush University Medical Center Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Also Published As

Publication number Publication date
CN113473981A (zh) 2021-10-01
EA202192199A1 (ru) 2021-12-17
EP3930704A4 (en) 2022-11-16
US20220133664A1 (en) 2022-05-05
KR20210130772A (ko) 2021-11-01
US12478598B2 (en) 2025-11-25
EP3930704A1 (en) 2022-01-05
WO2020176432A1 (en) 2020-09-03
CA3130761A1 (en) 2020-09-03
JP2022521233A (ja) 2022-04-06

Similar Documents

Publication Publication Date Title
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
AU2022200277A1 (en) The use of a benzoate containing composition to treat glycine encephalopathy
MXPA05002827A (es) Formulaciones farmaceuticas de modafinil.
US20160331714A1 (en) The use of a benzoate containing composition in urea cycle disorders and neurodegenerative disorders
Humble et al. Staphylococcal bacteraemia, fusidic acid, and jaundice.
US20230255910A1 (en) Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
JP2022521233A5 (enExample)
US20130084334A1 (en) Pharmaceutical compositions highly dosed with biotin
US20240216342A1 (en) Blood carnitine-increasing agent
HUT50440A (en) Process for producing pharmaceutical compositions for treating schizophrenia
EP2853261B1 (en) Agent for improving vesicourethral dyssynergia
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
US20240082184A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
EP3999051B1 (en) Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease
US20240100008A1 (en) Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
CN114073705B (zh) 一种降尿酸药物组合物及其应用
WO2017113775A1 (zh) 甘油三酯类化合物在制备治疗神经退行性疾病药物中的应用
HK40075156A (en) Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease
HK40075156B (en) Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period